Malignant salivary gland tumours in Sweden 1960–1989—An epidemiological study

doi:10.1016/S0964-1955(96)00077-2

Oral Oncology

Volume 33, Issue 3, May 1997, Pages 169-176

https://doi.org/10.1016/S0964-1955(96)00077-2 Get rights and content

Epidemiological data from the Swedish Cancer Registry of new cases of malignant major and accesssory salivary gland tumours in Sweden between 1960 and 1989 are presented, including the total number and the age-standardised incidence rate per 1 million population, by site and sex, I^(s). An analysis of the various histopathological types of malignant salivary gland tumours in the different sublocations is also given. A comparison is made between the three 10-year periods 1960–1969, 1970–1979 and 1980–1989 regarding total number and I^(s). The total number of new malignant major salivary gland tumours was 2557, representing approximately 85 new cases per year and 0.3% of all new diagnosed cancers in Sweden. In addition, approximately 25 new cases per year of malignant accessory salivary gland tumours were reported. If all malignant salivary gland tumours were considered, the most common location was found in the parotid glands with a relative frequency of 57.5%, and the next most common site was malignant accessory salivary gland tumours with 22.6%. I^(s) was 10.2 for the major and 3.0 for the accessory salivary glands. No major difference between the examined 10-year periods was found concerning the relative frequency, and no statistically significant difference in I^(s) was found between the examined 10-year periods, except for a statistically significant decrease in the I^(s) between the time periods 1960–1969 and 1980–1989 for the multiple or unspecified malignant salivary glands from 0.5 to 1.4. A difference in the distribution of various histopathological types of malignant salivary gland tumours was observed between the different time periods. This was particularly valid for the diagnoses adenoid cystic carcinomas and mucoepidermoid carcinomas which increased in number and the diagnosis malignant salivary gland tumours of mixed type, which decreased in number during the examined time periods.

References (47)

WallaceA.C. et al.
Salivary gland tumors in Canadian Eskimos
Cancer
(1963)
DaviesJ.N.P. et al.
Salivary gland tumors in Uganda
Cancer
(1964)
LokeY.W.
Salivary gland tumours in Malaya
British Journal of Cancer
(1967)
DollR. et al.
Evans RW, Cruickshank AH. Epithelial Tumours of the Salivary Glands. Philadelphia, WB Saunders,...
LennoxB. et al.
Incidence of salivary gland tumours in Scotland
Accuracy of national records
British Medical Journal
(1978)
GunnA. et al.
Parotid tumours: A review of parotid tumour surgery in the Northern Regional Health Authority of the United Kingdom 1978–1982
British Journal of Surgery
(1988)
ThomasK.M. et al.
Salivary gland tumors in Malawi
Cancer
(1980)
TakeichiN. et al.
Salivary gland tumors in atomic bomb survivors, Hiroshima, Japan: II. Pathologic study and supplementary epidemiologic observations
Cancer
(1983)
PulsenP. et al.
Benign and malignant neoplasms of the parotid gland
Incidence and histology in the Danish county of Funen
Laryngoscope
(1987)

DornH.F. et al.

Morbidity from cancer in the United States

SEER

Report on the status of cancer control, May 1989

JensenO.M. et al.

Cancer registration in Denmark and the study of multiple primary cancers, 1943–80

NCI Monographs

(1985)

NielsenN.H. et al.

Incidence of salivary gland neoplasms in Greenland with special reference to an anaplastic carcinoma

Acta Pathologica Microbiologica Immunologica Scandinavica

(1978)

MenckH.R. et al.

Cancer incidence patterns in the pacific basin

NCI Monographs

(1982)

EllisG.L. et al.

Classification of salivary gland neoplasms

SpiroR.H.

Salivary neoplasms: Overview of a 35-year experience with 2.807 patients

Head and Neck Surgery

(1986)

EnerothC.M.

Salivary gland tumors in the parotid gland, submandibular gland, and the palate region

Cancer

(1971)

SeifertG. et al.

Disease of the Salivary Glands. Pathology. Diagnosis—Treatment—Facial Nerve Surgery

(1986)

EvesonJ.W. et al.

Salivary gland tumours: A review of 2.410 cases with particular reference to histologic types, site, age, and sex distribution

Journal of Pathology

(1985)

FooteF.W. et al.

BatsakisJ.G.

Tumors of the Head and Neck: Clinical and Pathological Considerations

ThackrayA.C. et al.

Histologic Typing of Salivary Gland Tumours. WHO International Classification of Tumours No 4

(1971)

Cited by (76)

Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer
2020, Oral Oncology
Aim of the study was to evaluate the prognostic impact of CD8-positive (CD8⁺) tumour-infiltrating lymphocytes (TILs) and PD-L1 expression on the outcome of patients with malignant salivary gland neoplasms.
Formalin-fixed, paraffin-embedded tissue samples and clinicopathological data from patients treated for salivary gland carcinoma in a head and neck cancer centre were retrospectively retrieved. Immunohistochemical staining was applied on sections of 84 specimens of 12 different histological subtypes. Both CD8 and PD-L1 expression were rated by semi-automated cell counts by a digital image analysis programme. Survival analyses were performed by the log-rank test on the univariate level, and the Cox model was applied on the multivariate level. Associations between immunological markers and clinicopathological variables were estimated by the Pearson chi-squared test. Additionally, PD-1 was estimated as an exhaustion marker of CD8⁺ TILs.
Patients exceeding a tumour proportion score ≥5% regarding PD-L1 expression demonstrated a significantly decreased survival, as did individuals with an overall high CD8⁺ cell density. Particularly, high CD8⁺ cell counts in the invasive front of the respective tumour tissue significantly coincided with a poor outcome. Also, high numbers of CD8⁺ TILs significantly matched with a high quantity of PD-1⁺ TILs.
CD8⁺ TILs abundance in the peritumoural microenvironment correlates with impaired outcome of patients with salivary gland carcinoma. The simultaneous negative prognostic impact of PD-L1 expression and presence of PD-1⁺ TILs advocates an immune checkpoint-controlled mechanism of CD8⁺ TILs exhaustion for these tumours and paves the way for future treatment strategies.
Rates of tumour recurrences and metastases after surgical removal of malignant salivary gland tumours throughout 5-years of follow-up: A retrospective single-centre study
2019, Oral and Maxillofacial Surgery Cases
Citation Excerpt :
Moreover, Ladeinde et al. [7] reported that MSGTs represented 60.8% of all salivary gland tumours, while benign tumours accounted for 40.2% of their cases. Although, there are many studies [5,8–10], which have examined the demography of benign salivary gland tumours, studies examining MSGTs are rare [11,12]. General management guides for such tumours are available, but they vary from centre to centre [13,14] so the management of carcinomas are still discussable.
The purpose of the current study was to evaluate the frequency rates of tumour recurrences and rates of metastases in patients with surgical removal of malignant salivary gland tumours throughout 5 years of follow-up after initial therapy, and determine which salivary gland and histological diagnosis are the major contributors for the occurrence.
Between 2005 and 2017, 74 patients underwent surgical removal of localized malignant cancers of the salivary glands. Data were analysed retrospectively from our tertiary hospital database. The demographic characteristics (age and gender) were obtained from the patients' records. Pearson's χ-square test and logistic regression were used to analyse the data with p < 0.05 as statistically significant.
Malignant salivary gland tumours were mostly diagnosed at parotid gland in 51.4% of cases, thus majority of patients underwent surgical extirpation (37.8% of cases) of tumour removal. Adenocarcinoma was the most common form of malignancy (19 patients, 25.6%), followed by adenoid cystic carcinoma (13 patients 17.6%) and mucoepidermoid carcinoma (11 patients, 14.9%). Postoperative complications; namely tumour recurrences were detected in 8 patients (10.8%) throughout 5 years of follow-up after initial therapy. Metastases were observed in 6 patients (8.1%), and facial nerve paralyses were diagnosed in 19 (25.7%) of all patients and with no specific risk factors, that could have contributed to the occurrence of nerve damage.
A significant proportion of patients who are presumed to be cured of their disease through 5 years after initial treatment for salivary gland cancer will be found to develop late disease recurrences or metastases.
Salivary gland tumours in a northern Chinese population: a 50-year retrospective study of 7190 cases
2017, International Journal of Oral and Maxillofacial Surgery
The aims of this study were to investigate the epidemiological and clinical characteristics of epithelial salivary gland tumours in a northern Chinese population and to evaluate the current TNM classification system. A demographic and descriptive analysis of 7190 epithelial salivary gland tumours was performed. There were 4654 benign tumours and 2536 malignant tumours. The percentage of tumours located in the parotid, submandibular, sublingual, and minor salivary glands was 62.66%, 9.92%, 2.57%, and 24.85%, respectively; 22.26%, 35.76%, 92.97%, and 61.89% of the tumours, respectively, were malignant. Over 90% in the tongue and maxillary sinus were malignant. Warthin tumour, salivary duct carcinoma, and squamous cell carcinoma were predominant in males, while basal cell adenoma, myoepithelioma, and pleomorphic adenoma were predominant in females. Further, 2.55% of the tumours were in children and adolescents: 44.81% of the tumours were malignant, as opposed to 35.02% in adults. According to the 7th TNM classification, the percentages of T3 and stage III tumours were approximately 10%. Salivary gland tumours show distribution patterns according to histological type, location, and patient age and sex. The limitations of the current TNM classification of salivary gland carcinoma should be considered and revisions made.
Malignant sublingual gland tumors: Demographics, prognostic factors, and treatment outcomes
2016, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Citation Excerpt :
However, squamous cell carcinoma presented with a higher than expected frequency. It is likely that some of the squamous cell carcinomas identified in this study may have mucosal origins rather than sublingual gland origins.9 Past studies have found that most patients presented with an advanced stage at presentation (stage III or IV) because most sublingual tumors are asymptomatic.10,12,13
To determine the demographic characteristics, prognostic factors, and optimal treatment modalities of patients diagnosed with malignant primary tumors of the sublingual gland.
The Surveillance, Epidemiology, and End Results (SEER) registry contains 210 patients diagnosed with sublingual gland tumors in the SEER database. Kaplan-Meier and multivariate Cox regression analysis were performed on age, sex, race, histologic subtype, stage, and treatment modality.
Kaplan-Meier analysis found an overall survival and disease-specific survival at 5 years of 69% and 83%, respectively. Multivariate analysis demonstrated that age, sex, stage, and surgery were predictors of overall survival, whereas stage was a predictor of disease-specific survival.
Here we report, to our knowledge, the largest study to date investigating demographic characteristics, prognostic factors, and treatment modalities of patients diagnosed with primary malignant tumors of the sublingual gland. Increased age and stage correlated with decreased survival, whereas female gender and surgical therapy correlated with increased survival in the overall population. Radiation therapy for patients diagnosed with adenoid cystic carcinoma in the sublingual gland was correlated with increased survival.
An epidemiological evaluation of salivary gland cancer in the Netherlands (1989-2010)
2015, Cancer Epidemiology
The relative 5-year survival rate of salivary gland cancer is moderate at best. This study was set up to evaluate whether the improvements in diagnosis and treatment in the last decades impacted the incidence, mortality and survival of salivary gland cancer.
Data on patients with salivary gland cancer from 1989 through 2010 were extracted from the Netherlands Cancer Registry (NCR); we examined incidence, mortality and relative survival. Furthermore, information on sex, age, tumor stage, histology, and treatment was taken into account.
A total of 2737 patients were included. Fifty-three percent (53%) were males and 47% were females with a significant higher proportion of early stages in women. In 2010, the incidence rate (European Standardized Rate (ESR)) of salivary gland cancer was 0.9 per 100,000 per year. The estimated annual percentage change in incidence rate since 1989 equaled 0.6% (95%CI: −0.2–1.4). Mortality rates (ESR) decreased in men until 1997 and increased thereafter. Mortality in women remained stable at 1.5 per 100,000.
Over time more patients were treated by surgery and radiotherapy (p < 0.001). The relative five-year survival rate equaled 69% and did not change in time.
We observed no relevant changes in incidence or mortality rates in the last two decades. Despite the increased combined treatment by surgery and radiotherapy, survival did not improve. This implies an urgent need for the development of new effective treatment modalities.
Tumours of the salivary glands in northeastern China: A retrospective study of 2508 patients
2015, British Journal of Oral and Maxillofacial Surgery
Citation Excerpt :
The estimated global incidence ranges from 0.4 to 13.5 cases/100,000 annually.3 The incidence of malignant tumours of the salivary gland varies from 0.4 to 2.6 cases/100,000 inhabitants.4 In China, they account for only about 2% of human tumours,5 and about 5% of all malignant tumours in the head and neck region,6,7 with an incidence of 1.0/100,000 person/year.
Little information has been published in English about the epidemiology of tumours of the salivary glands in northeastern China. From August 2004 to March 2014, 2508 cases of primary epithelial salivary gland tumours were diagnosed in the Department of Oral and Maxillofacial Surgery, the Affiliated Stomatology Hospital of China Medical University. Tumours were analysed according to their histological type and site, and the age and sex of the patients. Ages ranged from 5 to 98 years, with a slight propensity in favour of men. The peak incidence was in the sixth decade for both sexes. The mean (SD) ages were 48 (16) years when the tumour was benign and 51 (15) years when it was malignant. The parotid gland and palate were the sites most commonly affected. There were 1934 (77.1%) benign and 574 (22.9%) malignant tumours, with the most common histological types being pleomorphic adenomas and mucoepidermoid carcinomas. A lesion that arises from the floor of the mouth (92.8%) or the tongue (86.2%) is more likely to be malignant than those from other minor salivary glands.

View all citing articles on Scopus

View full text

Malignant salivary gland tumours in Sweden 1960–1989—An epidemiological study

Salivary gland tumors in Canadian Eskimos

Cancer

Salivary gland tumors in Uganda

Cancer

Salivary gland tumours in Malaya

British Journal of Cancer

Incidence of salivary gland tumours in Scotland

Accuracy of national records

British Medical Journal

Parotid tumours: A review of parotid tumour surgery in the Northern Regional Health Authority of the United Kingdom 1978–1982

British Journal of Surgery

Salivary gland tumors in Malawi

Cancer

Salivary gland tumors in atomic bomb survivors, Hiroshima, Japan: II. Pathologic study and supplementary epidemiologic observations

Cancer

Benign and malignant neoplasms of the parotid gland

Incidence and histology in the Danish county of Funen

Laryngoscope

Morbidity from cancer in the United States

Report on the status of cancer control, May 1989

Cancer registration in Denmark and the study of multiple primary cancers, 1943–80

NCI Monographs

Incidence of salivary gland neoplasms in Greenland with special reference to an anaplastic carcinoma

Acta Pathologica Microbiologica Immunologica Scandinavica

Cancer incidence patterns in the pacific basin

NCI Monographs

Classification of salivary gland neoplasms

Salivary neoplasms: Overview of a 35-year experience with 2.807 patients

Head and Neck Surgery

Salivary gland tumors in the parotid gland, submandibular gland, and the palate region

Cancer

Disease of the Salivary Glands. Pathology. Diagnosis—Treatment—Facial Nerve Surgery

Salivary gland tumours: A review of 2.410 cases with particular reference to histologic types, site, age, and sex distribution

Journal of Pathology

Tumors of the Head and Neck: Clinical and Pathological Considerations

Histologic Typing of Salivary Gland Tumours. WHO International Classification of Tumours No 4